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7 CURRENTOPINION Molecular tests for the detection of antimicrobial
resistant Neisseria gonorrhoeae: when, where, and
how to use? Copyrig
0951-7375 Copyright  2016 Woltea bNicola Low and Magnus UnemoPurpose of review
Molecular methods for the diagnosis of Neisseria gonorrhoeae are replacing bacterial culture in many
settings. This review focuses on recent progress in the development of molecular tests to detect resistant
N. gonorrhoeae both to enhance surveillance and to guide decisions about individual patient
management.
Recent findings
Assays to enhance surveillance have been developed to detect determinants of resistance for all antibiotics
used as first-line gonorrhoea treatment, or to detect specific ‘superbug’ strains, but few have been applied
in clinical practice. The most advanced strategy relevant to individual case management is to identify
ciprofloxacin-sensitive strains so that unnecessary use of ceftriaxone can be avoided. Cross-reactivity with
pharyngeal commensal Neisseria species reduces specificity and is a challenge for many assays.
Summary
Progress with laboratory-based molecular tests to detect gonococcal resistance is being made but
substantial challenges remain. No laboratory-based assay has been subjected to a field evaluation and no
assay so far can be used as a point-of-care test. Given the threat of antimicrobial resistance, now is the
time to exploit the molecular technologies used for diagnosis and to invest in the development of molecular
gonococcal resistance tests that can be implemented for public health good.
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Antimicrobial resistant Neisseria gonorrhoeae is a
global public health challenge [1]. New diagnostic
strategies and novel antimicrobials are urgently
needed to conserve ceftriaxone [2], the last antimi-
crobial for empirical first-line monotherapy for gon-
orrhoea in many countries [3,4
&
]. Gonococcal
strains with resistance to extended-spectrum ceph-
alosporins have caused treatment failure with cef-
triaxone and/or cefixime in Europe, North America,
Asia, and Africa [5–9]. In this evolving situation,
dual antimicrobial therapy (ceftriaxone plus azi-
thromycin) has been introduced for first-line treat-
ment in Europe, Australia, and the United States
[10].
Detection of antimicrobial resistant gonococci
using molecular methods is a necessary innovation
[2,6,11,12] because nucleic acid amplification
tests (NAAT) are now the most widely used assays
for gonorrhoea diagnosis in many countriesht © 2016 Wolters Kluwe
rs Kluwer Health, Inc. All rights rese[11,13,14
&&
,15]. The WHO global action plan to mit-
igate the spread of multidrug-resistant gonococci
calls for increased surveillance of antimicrobial resist-
antN. gonorrhoeae globally, strengthened capacity for
bacterial culture and research into molecular
methods to monitor and detect resistance [1]. We
searched the US National Library of Medicine (Ovid
Medline) using the medical subject headings ‘Neisse-
ria gonorrhoeae’ or ‘gonorrhea’, ‘drug resistance,r Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com
KEY POINTS
 Molecular methods are increasingly used for
gonorrhoea diagnosis but, despite the global threat of
antimicrobial resistance, commercially available
diagnostic assays do not detect gonococcal
resistance determinants.
 The requirements of molecular tests to detect
gonococcal resistance depend on the purpose of the
assay; to enhance surveillance of antimicrobial
resistance, or to guide the clinical management
of gonorrhoea.
 Molecular detection of resistance determinants in
genital and rectal specimens is most accurate; cross-
reactivity with nongonococcal Neisseria species
particularly in the pharynx reduces assay specificity.
 Detection of ciprofloxacin resistance or susceptibility to
spare the use of extended-spectrum cephalosporins is
the strategy that has advanced the furthest to date, but
is not a long-term solution.
 Now is the time to exploit the molecular technologies
used for diagnosis and to invest in the development of
molecular gonococcal resistance tests that can be
implemented for public health good.
Sexually transmitted diseasesbacterial’, and ‘nucleic acid amplification tech-
niques’ in September 2015. We selected articles
from this search, reference lists of review articles
[3,4
&
,6,14
&&
,16] and abstracts of the World STI &
HIV Congress 2015. We found no articles about
commercially available molecular assays that detect
genetic resistancedeterminants ofN. gonorrhoeae, but
the number of reports of laboratory-developed assays
is increasing [17
&
,18–20,21
&
,22–26,27
&
,28–38]. This
review examines the requirements, recent progress
and challenges for the molecular detection of anti-
microbial resistant N. gonorrhoeae in clinical speci-
mens from the point of view of the two main
functions of resistance testing: to enhance surveil-
lance [14
&&
] and to guide decisions about individual
patient management [15]. We focus on publications
in the last 2 years about assays developed to detect
genetic determinants of N. gonorrhoeae resistance in
clinical specimens and for which results have been
compared with minimum inhibitory concentrations
(MICs) for specific antimicrobials.The need for molecular detection of
antimicrobial resistant Neisseria
gonorrhoeae
The molecular technologies have changed patterns
of gonorrhoea diagnosis in high-income countries.
NAAT are recommended because they have high Copyright © 2016 Wolters Kluwer 
46 www.co-infectiousdiseases.comsensitivity, robust specimen handling conditions,
can be automated with high throughput and can
be used on noninvasively collected samples like
first-void urine and vaginal swabs [39]. The rapid
adoption of NAAT has, however, raised two main
concerns about the ability to detect, monitor, and
manage antimicrobial resistance [1,6,11,14
&&
,15].
First, commercial NAAT specimens provide no via-
ble organism for antimicrobial susceptibility testing.
Second, as the number of specimens for culture falls
the microbiological skills required for isolation and
antimicrobial susceptibility testing are being lost [1].
Countries that have poor healthcare infrastructure
and rely on syndromic management of genitouri-
nary symptoms and/or microscopy of Gram-stained
smears have a particularly urgent need for better
diagnostics and knowledge of gonococcal antimi-
crobial resistance patterns [40].
Molecular technology is redefining expectations
about the detection of antimicrobial resistant gon-
orrhoea. The paradigm for sexually transmitted
infection treatment reflects the clinical priority to
treat symptomatic patients on presentation [3]. In
the absence of results of antimicrobial susceptibility
testing, the first-line treatment regimen should cure
at least 95% of infections [3]. Bacterial culture and
antimicrobial susceptibility testing underpin the
success of this strategy and have many advantages
[11,14
&&
]. First, culture on selective media directly
provides the biological material for assessing a
strain’s susceptibility to multiple antimicrobials
simultaneously [3]. Second, breakpoints for the
MIC that determines resistance correspond with
clinical treatment failure for many antimicrobials.
Third, organised surveillance programmes can
monitor changes in the resistance prevalence for
many antimicrobials [41–43]. Fourth, clinicians
can use the antimicrobial susceptibility profile to
alter therapy, or choose an antimicrobial for an
untreated patient. The use of NAATs alone precludes
monitoring of antimicrobial resistance, but has also
highlighted the limitations of culture. First, con-
siderable technical skills and time are required to
culture the fastidious N. gonorrhoeae and test for
antimicrobial resistance. Second, culture has poor
sensitivity for extragenital sites such as the pharynx
[3], where horizontal transfer of resistance determi-
nants from commensal Neisseria species is thought
to be the origin of resistance to extended-spectrum
cephalosporins [4
&
,6].Requirements of molecular tests to detect
antimicrobial resistant N. gonorrhoeae
Ideally, molecular resistance testing should reflect
the exact MICs of different antimicrobials.Health, Inc. All rights reserved.
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Table 1. Main genes associated with antimicrobial resistance in Neisseria gonorrhoeae
Antimicrobial Principal gene(s) and positiona
Other genes with verified impact
on resistance in clinical strainsa,c
Ciprofloxacin gyrA S91 (D95) parC
Ceftriaxone penA mosaic allele (A501-altered penA alleles) mtrR, porB
Azithromycin 23S rRNA gene: C2611 (lower level of resistance) and A2059
(high-level resistance)b
mtrR, mefA, erm genes
Spectinomycin 16S rRNA gene: C1192 rpsE
Tetracycline tetM-carrying plasmid (high-level resistance) and rpsJ V57 (lower
level of resistance)
mtrR, porB
Penicillin b-lactamase plasmid (blaTEM gene; high-level resistance) and penA
(D345 insertion or mosaic allele; lower level of resistance)
mtrR, porB, ponA
aWith the exception of the tetM-carrying plasmid and the b-lactamase plasmid, listed genes, and positions are involved in chromosomally-mediated resistance.
Wild type positions are listed, which can have many different mutations resulting in resistance.
bThere are four alleles of the 23S rRNA gene in each gonococcal strain. Escherichia coli numbering used.
cThere are additional efflux pumps, for example, MacAB and NorM, in N. gonorrhoeae that affect the minimum inhibitory concentrations of several
antimicrobials.
Detection of antimicrobial resistant Neisseria gonorrhoeae Low and UnemoResistance to many antimicrobials inN. gonorrhoeae,
however, is affected by multiple genes. Different
mutations and an accumulation of these mutations
result in the high MIC of the specific antimicrobial
[4
&
]. This characteristic makes it exceedingly diffi-
cult to use molecular assays to predict exact MICs of
antimicrobials, but by targeting the main resistance
determinants the resistance/susceptibility pheno-
typesmight be predicted. The principal genes associ-
ated with gonococcal antimicrobial resistance are
shown in Table 1.
Most publications about molecular tests to
detect gonococcal resistance determinants report
their intended use for surveillance purposes
[17
&
,18–20,21
&
,22–26,27
&
,28–31]. Fewer mention
the need or potential for guiding individual patient
management [18,27
&
,31–35]. There are many simi-
larities in the requirements for assays for both pur-
poses. For example, the capacity for direct detection
in clinical specimens [17
&
,18,19,21
&
,24,26,27
&
,
29–32,44
&
] is critical if the assays are to be used in
situations where bacterial culture has not been per-
formed. Table 2 lists similarities and differences
between test requirements for surveillance and
clinical management.Enhancing surveillance of antimicrobial
resistant N. gonorrhoeae
Experts agree that molecular tests can enhance but
not replace culture-based surveillance [1,4
&
,6,14
&&
].
The lack of correspondence between genetic resist-
ance determinants, MICs and clinical treatment
failure, particularly for evolving resistance in
extended-spectrum cephalosporins, remains a
critical stumbling block [6]. Nevertheless, molecular
assays to enhance surveillance can advance more
quickly than those for clinical management partly Copyright © 2016 Wolters Kluwe
0951-7375 Copyright  2016 Wolters Kluwer Health, Inc. All rights resebecause the assays can be solely laboratory-based,
short reaction times are not essential and sensitivity
and specificity can be suboptimal [26,31] (as long as
they allow consistent monitoring of trends) because
the results will not influence individual patient
management (Table 2). As new resistant strains
emerge or levels of recognised resistance increase,
culture-based surveillance can be broadened to
confirm the findings of molecular tests.
Some assays have been used in real-life settings.
A real-time polymerase chain reaction (PCR) assay
was developed to detect penicillinase producing
gonococci [30] in remote regions of Australia where
resistance to penicillin remains below 5%. The
molecular assay had 100% sensitivity and 98.7%
specificity compared with phenotypic tests. When
applied subsequently to N. gonorrhoeae positive
NAAT specimens from Western Australia, the assay
detected penicillinase producing gonococci in
15/915 (1.6%) of specimens from remote areas
and 34/303 (11.2%) of specimens frommore heavily
populated areas [44
&
]. As a result, the treatment
regimen of amoxicillin, probenecid, and azithromy-
cin was continued in remote areas and, in populous
areas, changed from ceftriaxone alone to ceftriaxone
plus azithromycin [44
&
]. This assay has been further
optimised to include additional b-lactamase plas-
mid targets [19]. Molecular tests for surveillance can
also be used tomonitor specific strains. For example,
real-time PCR assays have been developed to screen
clinical specimens for extensively drug resistant
gonococcal strains (‘superbugs’) that were first
detected in Japan (H041) [29] and subsequently in
Europe (F89) [24].
An antibiogram gives information about
susceptibility to multiple antimicrobials. Most mol-
ecular assays detect resistance determinants and
relate to a single antibiotic (penicillin [19,30,44
&
];r Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com 47
Table 2. Requirements of molecular tests to detect antimicrobial resistant Neisseria gonorrhoeae
Clinical management
Characteristic Surveillance Asymptomatic patient Symptomatic patient
Specimen type Culture or clinical specimen Culture or clinical specimen Clinical specimen
Location of test equipment Laboratory Laboratory or point-of-care Point-of-care
Time from sample collection to
reporting result
Not critical Same as or quicker than culture-
based testing
Minimal
Technical skill required Skilled laboratory technician Skilled laboratory technician or
minimal
Minimal
Skill required to interpret results Minimal–high Minimal–intermediate Minimal
Accuracy Intermediate–high High High
Cost Low–high Low–intermediate Low
Scalable Not critical Desirable Critical
Multiplex Not critical Desirable Critical
Sexually transmitted diseasesciprofloxacin [18,31,32]; azithromycin [21
&
,45];
extended-spectrum cephalosporins [17
&
]); or a
single strain [24,29]. Molecular assays aiming to
detect resistance to several antimicrobials have been
run in series [26] or as multiplex reactions [27
&
,36],
but their analytical sensitivity was too low to be used
in clinical specimens [36] or, if assessed on clinical
specimens, was not validated against a culture-based
MIC reference standard [26,27
&
].Laboratory-based molecular tests to guide
individual patient management
Laboratory-based molecular assays could have
advantages if they produce faster results and have
greater sensitivity than bacterial culture, particu-
larly when used on extragenital specimens for NAAT
testing. Laboratory-based assays will usually not
help, however, in the management of patients
who present with symptoms or who need same-
day treatment for other reasons.
The strategy that has advanced furthest aims to
spare overuse of ceftriaxone plus azithromycin (the
only remaining first-line empirical treatment in
many countries) by targeting ciprofloxacin to
patients with ciprofloxacin-sensitive gonococcal
strains before treatment is initiated. Several labora-
tory-based molecular assays for use in clinical speci-
mens detect one or more chromosomal mutations
in gonococci that are associated with ciprofloxacin
resistance [18,26,27
&
,31,32]. Siedner and colleagues
[31] designed a real-time PCR assay to detect resist-
ance using a single target mutation in urine speci-
mens. A single nucleotide polymorphism in amino
acid codon S91 in the gyrA gene is found in all
ciprofloxacin resistant strains, even though
additional mutations in gyrA and other loci (Table
1) contribute to higher levels of resistance [4
&
,46]. Copyright © 2016 Wolters Kluwer 
48 www.co-infectiousdiseases.comThe prototype assay amplified the target sequence in
only 85% of all urine NAAT specimens tested [31].
Further optimisation of this assay has improved
sensitivity in cultured isolates, which should be
validated in clinical specimens [37]. The suboptimal
diagnostic test accuracy of real-time PCR assays to
detect ciprofloxacin resistance in clinical specimens
presents ongoing challenges. In a study that tested
24 NAAT specimens, real-time PCR assays correctly
identified only 4/6 ciprofloxacin-resistant speci-
mens with S91 mutations and 16/18 ciprofloxa-
cin-sensitive specimens [18]. Three of four
specimens that failed were from the pharynx or
rectum. Cross-reactivity occurred with N. meningi-
tidis, N. lactamica, N. subflava, and N. polysaccharea.
In another study, real-time PCR failed in 10% (28/
290) of clinical specimens, particularly those from
nongenital sites [38].
An alternative strategy is to identify wild type
gyrA sequences that predict ciprofloxacin suscepti-
bility rather than resistance [32]. To exclude cross-
reactivity, aN. gonorrhoeae specific target (dcmH) was
also detected in this molecular assay. When used in
male urine NAAT specimens in South Africa, the
assay correctly identified 15/15 ciprofloxacin-sensi-
tive and 18/18 strains with intermediate suscepti-
bility or resistance [32].Point-of-care molecular tests to guide
individual patient management
Point-of-care tests have a rapid turnaround time that
guides clinical decisions and allows results and treat-
ment to be given to the patient at the same visit [47].
None of the molecular assays developed so far to
detect antimicrobial resistance in N. gonorrhoeae is a
‘transformative point-of-care diagnostic test that
will conserve antibiotics for future generations. . .Health, Inc. All rights reserved.
Volume 29  Number 1  February 2016
Detection of antimicrobial resistant Neisseria gonorrhoeae Low and Unemo(and is) accurate, rapid, affordable, easy-to-use and
available to anyone, anywhere in the world’ [48].
These criteria, set by the Longitude Prize, aim to
stimulate innovation in diagnostic test develop-
ment for all infectious diseases. Even the GeneXpert
(Cepheid, Sunnyvale, Washington, USA) tests for
gonorrhoea/chlamydia diagnosis are not rapid
point-of-care tests because the NAAT takes 90min,
rather than a 30-min benchmark set by inter-
national groups, and their high cost precludes wide-
spread use [40,48,49].
The requirements of a point-of-care test focusing
on accurate and cost-effective detection of a limited
number of targets without the need for separate
DNA extraction methods [50] need to be differenti-
ated from tests for surveillance, which might detect
many resistance determinants in multistage multi-
plex assays [27
&
] (Table 2). Advances in bioengineer-
ing and nanotechnology, such as microfluidics, will
help to adapt laboratory-based systems to clinic-
based formats [40,51]. Target product profiles that
define the user, patient population, and point-of-
care device requirements are essential [47]. Evalu-
ation trials should use clinically relevant endpoints
[40,52], such as prediction of resistant phenotypes
and reduced antibiotic prescribing. The ideal system
would detect bothN. gonorrhoeae and its main resist-
ance determinants at the point-of-care and allow
individualised antimicrobial treatment to help slow
the spread of antimicrobial resistance, particularly
in resource-poor settings.
Molecular detection of extended-spectrum
cephalosporin resistance
Resistance to extended-spectrum cephalosporins
remains the most urgent threat. The development
of molecular assays to detect any resistance to
extended-spectrum cephalosporins in clinical speci-
mens is inherently challenging because multiple
mechanisms are involved and are still evolving
[4
&
]. Mosaic alleles of the penA gene encoding
penicillin-binding protein 2 (PBP2) and nonmosaic
penA alleles with A501 mutations are the main
determinants of decreased susceptibility and resist-
ance to extended-spectrum cephalosporins [4
&
]. The
gonococcal ‘superbug’ F89 strain is a good example
of how resistance to extended-spectrum cephalo-
sporins evolves. This strain contains a penA mosaic
allele (type XXXIV), which is common worldwide
[4
&
,5–7], with an additional A501P alteration, result-
ing in high-level ceftriaxone resistance [9]. Molecu-
lar test specificity is a major challenge, particularly
for pharyngeal specimens that frequently harbour
nongonococcal Neisseria species with similar penA
sequences. Several assays have examined the pres-
ence of mosaic penA allele sequences in cultured Copyright © 2016 Wolters Kluwe
0951-7375 Copyright  2016 Wolters Kluwer Health, Inc. All rights reseisolates [25,50,53]. One real-time PCR assay that
detects N. gonorrhoeae ( porA pseudogene), mosaic
penA alleles and mutations in additional resist-
ance-determining loci (mtrR, porB, and ponA) was
tested on 24 gonococcal-negative NAAT specimens
and 34 gonococcal-positive NAAT specimens [17
&
].
The assay detected a mosaic penA allele in one speci-
men with the highest ceftriaxone MIC (0.25mg/ml),
but lacked specificity in the prediction of decreased
susceptibility to extended-spectrum cephalosporins
(in clinical specimens and culture isolates). This
suboptimal specificity will be exceedingly difficult
to overcome because this assay and other similar
assays detect many different mosaic penA alleles
which result in highly divergent MICs of the
extended-spectrum cephalosporins [4
&
,6,8]. Further-
more, cross-reactivity in the penA, mtrR, porB, and
ponA targets with commensal Neisseria isolates or in
clinical specimens was identified. All three clinical
cross-reactive specimens were from the pharynx
[17
&
].
Molecular detection of azithromycin
resistance
Azithromycin alone is not a first-line treatment for
gonorrhoea, but detecting resistance is important
because of its use in dual treatment regimens. Two
mutations in the 23S ribosomal RNA genes (A2059G
and C2611T) are associated with azithromycin
resistance with MICs depending on how many of
the four alleles are mutated [45,54]. Two real-time
PCR assays could characterise the 23S rRNA 2059
and 2611 positions as wild type or mutated in 87%
(266/306) of genital and rectal specimens. However,
cross-reactivity was observed with both assays test-
ing commensal Neisseria species and in 33% (7/21)
of pharyngeal samples [21
&
]. Furthermore, among
64 samples with MIC results, 3% (2/64) with raised
MICs (1mg/ml), which indicates resistance, were
identified as 23S rRNA wild type.
Challenges for molecular detection of
antimicrobial resistant N. gonorrhoeae
The number of assays and techniques used to detect
genetic determinants of antimicrobial resistant
N. gonorrhoeae is increasing and some assays are
beginning to be adopted for surveillance [14
&&
].
Progress in molecular assays to guide clinical man-
agement, however, is lagging. In addition to the
challenges to developing usable and commercially
viable point-of-care tests [47], there are many
remaining roadblocks for the development of diag-
nostic tools to contain antimicrobial resistance in
general [40] and for gonorrhoea in particular. First,
molecular tests can only detect known targets and
new mutations and resistance mechanisms willr Health, Inc. All rights reserved.
rved. www.co-infectiousdiseases.com 49
Sexually transmitted diseasesdevelop for both extended-spectrum cephalosporins
and other antimicrobials. Adaptable assays and
maybe new technologies such as whole genome
sequencing might be required to overcome this
challenge. Second, incomplete understanding of
the relationship between genetic resistance deter-
minants and phenotypic resistance [4
&
] needs to be
overcome to improve the validity of evaluation
studies. Third, diagnostic evaluation studies that
compare detection of genetic resistance determi-
nants with MICs are small and their methodology
is subject to biases that overestimate test perform-
ance [52]. Larger field studies with blinded evalu-
ation of a range of specimen types and results are
needed. Fourth, test sensitivity and specificity are
still suboptimal for clinical specimens, particularly
for pharyngeal specimens. Some cross-reactivity
with nongonococcal Neisseria species that carry
the same genetic sequences cannot be overcome
but advances in primer and assay design might
improve test accuracy. Finally, diagnostic tests
can help to implement and monitor treatment
strategies to spare first-line empirical therapy
with ceftriaxone plus azithromycin. But targeting
ciprofloxacin treatment, using azithromycin as
co-therapy and other actions are short-term
solutions with unknown consequences for the
spread of antimicrobial resistant N. gonorrhoeae. In
the medium term, new therapeutic antimicrobials
are crucial. A gonococcal vaccine [55] is probably
the only long-term solution.CONCLUSION
Progress with the development of molecular tests
to detect gonococcal resistance is significantly
more advanced for enhancing surveillance than
for guiding clinical decision making but substantial
challenges remain. Gonococcal culture and antimi-
crobial susceptibility testing remain essential tools
for surveillance and as a reference standard for assay
validation. The prioritisation of molecular resist-
ance determinants for inclusion in assays needs to
consider both short and longer term antimicrobial
resistance threats. In addition, cross-reactivity with
nongonococcal Neisseria species, particularly in the
pharynx, is a challenge for all assays and suggests
that assay development should focus first on genital
and rectal clinical specimens. Now is the time to
exploit the molecular technologies used for diagno-
sis and to invest in the development of molecular
gonococcal resistance tests that can be implemented
for public health good.
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